leadf
logo-loader
viewNuminus Wellness Inc.
(
TSX-V:NUMIOTC:LKYSFFRA:LR23
)

Numinus Wellness files US patent application for its proprietary rapid psilocybin production process

The company said that its proprietary process “dramatically” increases the production of psychoactive fungi species that contain psilocybin

Numinus Wellness Inc. -
Numinus is hoping to scale up the technology to make psychedelic products from fungi more available

Numinus Wellness Inc (CVE:NUMI) has announced that its subsidiary Numinus Bioscience Inc has filed a provisional patent application in the US for the rapid production process that generates therapeutic products from psychoactive fungi.

Vancouver-based Numinus said that its proprietary process “dramatically” increases the production of psychoactive fungi species that contain psilocybin, generating therapeutics that can be used in psychedelic-assisted psychotherapy.

The process also produces other psychoactive compounds and other “beneficial” compounds, including some that Numinus researchers have characterized for the first time in psychedelic fungi, the company added.

READ: Numinus Wellness brings on five new executives to help support growth across Health, R&D and Bioscience divisions

Results from a test run revealed a highly efficient, scalable process that can be applied to other species of psychoactive fungi, Numinus noted. The firm said it will assess the clinical efficacy and safety of an extract generated using its proprietary technology in an upcoming Phase 1 clinical trial.

Numinus is hoping to scale up the technology to make psychedelic products from fungi more available if and when the market becomes more regulated in the future.

"The rapid production process announced today meets that goal by enhancing our ability to seamlessly formulate safe and effective products with consistent psychoactive properties at scale, with the regulatory confidence that comes with standardized products,” said Sharan Sidhu, Numinus Bioscience general manager and science officer in a statement.

Numinus CEO Payton Nyquvest added: "As research interest and demand for compassionate access to psychedelics grows, patients will require safe therapeutic products that offer consistent psychoactive properties and are scalable. With that in mind, we believe that the rapid production process has the potential to transform the sector and ensure that as many people as possible have the opportunity to benefit from mental health treatments and support their wellbeing."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Numinus Wellness Inc.

Follow
TSX-V:NUMI

Price: 0.81 CAD

Market Cap: $162.87 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Numinus Wellness gets Health Canada approval for open-label study for...

Numinus Wellness Medical and Therapeutic Services Director for Numinus Dr. Devon Christie joined Steve Darling from Proactive to announce Health Canada has cleared an open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder. Dr Christie, who...

on 07/27/2021

2 min read